The MINDACT trial (2016) established that in early breast cancer patients with high clinical risk but low genomic risk by 70-gene signature (MammaPrint), what proportion could safely forgo adjuvant chemotherapy?
- A About 30%
- B About 60%
- C About 46% ✓
- D About 75%
Correct answer: C. About 46%
Explanation
MINDACT showed that ~46% of patients with high clinical risk but low genomic risk had 5-year distant metastasis-free survival of 94.7% without chemotherapy, supporting genomic assay-guided de-escalation. This landmark trial validated MammaPrint in the clinical-high/genomic-low subgroup. The absolute chemotherapy benefit in this group was only ~1.5%, allowing safe omission.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.